SAP Depleter Dose Assessment Study in Patients

Summary

This study aims to provide safety information on the ligand, GSK2315698A. The pharmacokinetics and pharmacodynamics of the ligand will be determined together with the differences in routes of dose administration, namely the tolerability between intravenous versus subcutaneous dose administration. The study will be carried out in patients with systemic amyloidosis and the ability of GSK2315698A in depleting levels of serum amyloid protein (SAP) will be measured.

Timeline

Start

2011-10-13

Primary completion

2012-11-14

Completion

2012-11-14

Drugs

Indications